Stamp LK, et al. - In order to compile the evidence about rheumatoid arthritis (RA) patient perspectives on biologic tapering, researchers retrieved the currently small body of research on patient perspectives via performing systematic searches with an emphasis on seeking qualitative research. Observations revealed international variation in financial considerations around commencing/continuing on biologic therapies in RA and that these may have implications for patient perspectives. As per recent clinical studies, drug concentration and aspects of disease activity, severity and duration predict the benefit of tapering biologic therapy when in remission. From studies of patient perspectives on biologic tapering, they identified 3 major concerns : disease relapse; access to treatment in the case of disease flare when tapering; and local motivation for dose reduction (ie, driven by funding or health benefit).